vimarsana.com

Page 2 - ஐரோப்பிய சங்கம் ஆஃப் சிறுநீரகம் காங்கிரஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Chance of survival increases in obese patients with advanced prostate cancer

Chance of survival increases in obese patients with advanced prostate cancer Chance of survival increases in obese patients with advanced prostate cancer Last Updated: Sun, Jul 11th, 2021, 10:20:08hrs Amsterdam [Netherlands], July 11 (ANI): A new research has found that obese patients with a form of advanced prostate cancer survive longer than overweight and normal-weight patients. The study, presented today at the European Association of Urology Congress, EAU21, followed more than 1500 patients over three years. Patients classed as obese - with a BMI over 30 - had a ten percent higher survival rate than thinner patients over 36 months. Although obesity is usually associated with an increased risk of death from many cancers and some other chronic diseases, there is some evidence in a few cancers of a survival advantage for patients with a high body mass index. This phenomenon is known as the obesity paradox .

Risk of recurring kidney cancer can be reduced by using old drug at earlier stage

Risk of recurring kidney cancer can be reduced by using old drug at earlier stage ANI | Updated: Jul 11, 2021 08:51 IST Washington [US], July 11 (ANI): According to the findings of new research, using an existing drug for late-stage kidney cancer at an earlier stage of the disease could reduce the risk of cancer recurring by a third. The findings from the Phase III trial were presented at the European Association of Urology Congress (EAU21). There is a high risk of kidney cancer returning, following surgery to remove tumours, but there is currently no treatment to help prevent this. The KEYNOTE study involved just under 1000 patients with kidney cancer who had undergone surgery. Half of them were given the immunotherapy drug pembrolizumab, or pembro, and the other half a placebo.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.